Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Inhalation Sciences Sweden AB's Revenue for the
three
months ended in Mar. 2026 was kr4.15 Mil. Inhalation Sciences Sweden AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was kr1.13 Mil.
Hence, Inhalation Sciences Sweden AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 3.66.
Inhalation Sciences Sweden AB (XSAT:ISAB) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Inhalation Sciences Sweden AB Receivables Turnover Related Terms
Inhalation Sciences Sweden AB Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhalation Sciences Sweden AB Receivables Turnover Chart
XSAT:ISAB vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Inhalation Sciences Sweden AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhalation Sciences Sweden AB Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inhalation Sciences Sweden AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Inhalation Sciences Sweden AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhalation Sciences Sweden AB (XSAT:ISAB) has a Receivables Turnover of 3.66 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Inhalation Sciences Sweden AB and its competitors. According to the industry distribution chart, Inhalation Sciences Sweden AB ranks #208 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 25.6%.
Is Inhalation Sciences Sweden AB's Receivables Turnover too high?
Inhalation Sciences Sweden AB's current Receivables Turnover is 3.66. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Inhalation Sciences Sweden AB's value of 3.66 is 33.6% below this industry median. Based on the distribution chart, Inhalation Sciences Sweden AB ranks #208 out of 812 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Inhalation Sciences Sweden AB has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inhalation Sciences Sweden AB's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Inhalation Sciences Sweden AB ranks #208 out of 812 companies for Receivables Turnover. This puts Inhalation Sciences Sweden AB in the upper half of its industry. The industry median Receivables Turnover is 5.51. Inhalation Sciences Sweden AB's value of 3.66 is 33.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inhalation Sciences Sweden AB's current Receivables Turnover of 3.66 is 33.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Inhalation Sciences Sweden AB and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhalation Sciences Sweden AB's current Receivables Turnover is 3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhalation Sciences Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB (XSAT:ISAB) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.38, compared to a current price of kr0.19 — trading 50.8% below its estimated fair value. The current Receivables Turnover is 3.66 and 33.6% below the Medical Devices & Instruments industry median of 5.51. Inhalation Sciences Sweden AB's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Inhalation Sciences Sweden AB (XSAT:ISAB), the current Receivables Turnover is 3.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inhalation Sciences Sweden AB (XSAT:ISAB) Overvalued in 2026?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB stock appears to be undervalued.
The current stock price of kr0.19 is trading 50.8% below its estimated GF Value™ of kr0.38.
GuruFocus considers Inhalation Sciences Sweden AB to be Possible Value Trap.
Key valuation signals for XSAT:ISAB:
Receivables Turnover: 3.66
GF Value™: kr0.38 vs. price of kr0.19 (50.8% below fair value)
Industry Position: 33.6% below the Medical Devices & Instruments median (#208 of 812)
No single metric tells the full story. See the XSAT:ISAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inhalation Sciences Sweden AB develops and commercializes patented lab instrument for inhalation research. Its products include PreciseInhale an advanced laboratory system used to measure inhaled particles and their effect on lungs, and LaminarPace tool for drying small amounts of the drug substance.
29GF Score
Get the complete analysis for XSAT:ISAB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ISAB has been successfully added to your 
